A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Voluntarily sign the written Informed Consent Form (ICF) and consent to receive curative surgical treatment. 2. Participants must be aged ≥ 18 years, regardless of gender. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status Score is 0-1. 4. Histologically confirmed resectable Stage IIA-IIIB (N2) non-small cell lung cancer (NSCLC) according to the 9th edition of the TNM staging system for lung cancer by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). 5. Prior to study enrollment, subjects must be evaluated by an attending thoracic surgeon responsible for the surgery to verify eligibility for R0 resection with curative intent. 6. NSCLC appears solid or subsolid (not purely ground-glass opacity \[GGO\]) on CT scan. For subsolid lesions, tumor size (i.e., clinical T stage) should be based solely on the solid component without measuring the GGO portion. 7. Normal pulmonary function test results. 8. At l…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source